Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
| Journal Title: | The Lancet (British edition) 2010, Vol.375 (9721), p.1173-1181 |
| Main Author: | Bakris, George L, Dr, Prof |
| Other Authors: | Sarafidis, Pantelis A, MD , Weir, Matthew R, Prof , Dahlöf, Björn, Prof , Pitt, Bertram, Prof , Jamerson, Kenneth, MD , Velazquez, Eric J, MD , Staikos-Byrne, Linda, PhD , Kelly, Roxzana Y, MS , Shi, Victor, MD , Chiang, Yann-Tong, PhD , Weber, Michael A, Prof |
| Format: |
 Electronic Article
|
| Language: |
English |
| Subjects: | |
| Quelle: | Alma/SFX Local Collection |
| Publisher: | Kidlington: Elsevier Ltd |
| ID: | ISSN: 0140-6736 |
| Zum Text: |
SendSend as email
Add to Book BagAdd to Book Bag
Staff View
| recordid: | cdi_proquest_miscellaneous_879476971 |
| title: | Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial |
| format: | Article |
| creator: |
|
| subjects: |
|
| ispartof: | The Lancet (British edition), 2010, Vol.375 (9721), p.1173-1181 |
| description: | Summary Background The Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial showed that initial antihypertensive therapy with benazepril plus amlodipine was superior to benazepril plus hydrochlorothiazide in reducing cardiovascular morbidity and mortality. We assessed the effects of these drug combinations on progression of chronic kidney disease. Methods ACCOMPLISH was a double-blind, randomised trial undertaken in five countries (USA, Sweden, Norway, Denmark, and Finland). 11 506 patients with hypertension who were at high risk for cardiovascular events were randomly assigned via a central, telephone-based interactive voice response system in a 1:1 ratio to receive benazepril (20 mg) plus amlodipine (5 mg; n=5744) or benazepril (20 mg) plus hydrochlorothiazide (12·5 mg; n=5762), orally once daily. Drug doses were force-titrated for patients to attain recommended blood pressure goals. Progression of chronic kidney disease, a prespecified endpoint, was defined as doubling of serum creatinine concentration or end-stage renal disease (estimated glomerular filtration rate |
| language: | eng |
| source: | Alma/SFX Local Collection |
| identifier: | ISSN: 0140-6736 |
| fulltext: | fulltext |
| issn: |
|
| url: | Link |
| @attributes |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PrimoNMBib |
|